Corporate Profile

The cancer treatment paradigm has shifted dramatically over the last decade, providing evidence that the immune system can be reactivated against a patient’s tumor. At Candel Therapeutics, we are developing immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications. Candel’s products are designed to improve survival while maintaining quality of life – from early- to late-stage disease.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

SEC Filings

Filing date Description Form

EFFECT

EFFECT

Initial filing by director officer or owner of more than ten percent.

3

Initial filing by director officer or owner of more than ten percent.

3